Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

Type 2 Diabetes Clinical Trial

— T2DM  

Official title:

Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01805830
• Other study ID #: MP_C301
• Status: Completed
• Phase: Phase 3
• First received: December 26, 2012
• Last updated: October 5, 2015
• Start date: May 2012
• Est. completion date: September 2013

Study information

• Verified date: October 2015
• Source: Handok Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study design of this trial is double blind, parallel-group, randomized, Placebo controlled study.

Description:

• Although many different oral antidiabetic agents are currently available, approximately 50% of treated Type 2 diabetic subjects do not reach currently accepted goals for HbA1c(Oral communication, American Diabetic Association, 2008)

• Subjects are frequently prescribed agents which can cause hypoglycemia, and/or weight gain. Metformin does not usually have these unwanted effects, and it is the standard first line therapy in treating type 2 diabetic mellitus in European union.

• Nonclinical pharmacodynamic studies revealed that MP-513 effectively improves glucose tolerance in animal models of type 2 diabetes, whilst the compound has very little potential to cause hypoglycaemia, the most commonly reported adverse event with many currently marketed products.

• The nonclinical studies also suggested that the inhibitory effect of MP-513 on DPP-Ⅳ is more potent and durable than other DPP-Ⅳ inhibitors in development. The result in safety pharmacology and toxicology also revealed that MP-513 has a relatively wide margin for safety.

• Thus, MP-513 is expected to have good efficacy and tolerability in subjects with type 2 diabetes mellitus by once-daily administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 189
• Est. completion date: September 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject is aged =18 years at signature of the ICF

2. The subject has had a documented diagnosis of Type 2 diabetes for at least 6 months at the screening visit

3. The subject's Type 2 diabetes is managed by metformin monotherapy =1000 mg/day, plus diet and exercise, as appropriate, and the dose has been unchanged for at least 56 consecutive days

4. The subject's HbA1c is 7.0%=HbA1c<10.0%

5. The subject's BMI is 20.0=BMI=40.0kg/m2

6. The subject's FPG is <15 mmol/L (270 mg/dL)

7. The subject is capable of giving informed consent, complying with the restrictions and requirements of the protocol

Exclusion Criteria:

1. The subject is suffering from any disease, including Type 2 diabetes or its complications that, in the opinion of the Investigator, is sufficiently severe to render the subject unfit, or affect the subject's ability, to participate in the study, for example:

• Macroangiopathy with symptoms of coronary heart disease or peripheral arterial obstructive disease.

• Microangiopathy with symptoms of (autonomous) neuropathy with any one or more of the following: gastroparesis

• Symptoms of poor blood glucose control (polyuria, polydipsia or weight loss)

2. The subject has a history of Type 1 diabetes or a secondary form of diabetes

3. The subject has a history of allergy to MP-513, or to any of the excipients in the MP-513 tablet (eg. Mannitol)

4. The subject has a history of drug abuse

5. The subject drinks on average more than 28 units of alcohol per week(One unit of alcohol equals approximately 250 mL of beer, 125 mL of wine or 40 mL of spirits)

6. The subject has a medical history of unstable angina, or heart failure(New York Heart Association class ?-IV) or any clinically significant ECG abnormalities such as ventricular tachycardia or a medical history of ventricular tachycardia

7. The subject has participated in any other clinical study involving blood draws or administration of an unlicensed medicinal product within 12 weeks prior to the screening visit (This does not preclude a subject from being re-screened for this study at a later date within the 12 week period, provided they were not randomised )

8. The subject has received insulin within 12 months prior to the screening visit, with the exception of insulin therapy during hospitalization, insulin therapy for medical conditions not requiring hospitalization (<2 weeks duration) or use in gestational diabetes

9. The subject is suffering from serious concurrent renal disease or creatinine clearance <60 mL/min

10. Non-surgically sterilised, pre-menopausal female subject, who does not agree to use a double barrier method of contraception from the screening visit until at least 14 days after the last dosing day (Examples of permitted types of contraception are: condoms, cervical cap in conjunction with spermicide, sterilisation and intra-uterine device. Oral contraception is permitted but must not be used as the sole method of contraception)

11. Female subjects whose pregnancy test is negative or who are pregnant, lactating, or are planning to become pregnant during the study

12. The subject is expected to require additional diabetic treatment for his/her Type 2 diabetes or its complications during the study after the screening visit

13. The subject has a clinically significant liver disease with aspartate-amino-transferase (AST) and alanine-amino-transferase (ALT) >2.5 times the upper limit of normal (ULN) at the screening visit

14. The subject has diastolic blood pressure >100 mmHg and/or systolic blood pressure >180 mmHg at the screening visit

15. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Type 2 Diabetes

Intervention

Drug:
• MP513
form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
• Placebo
form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day

Locations

Country	Name	City	State
Korea, Republic of	Handok Pharmaceuticals CO. LTD	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Handok Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c		Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)	No
Secondary	FPG(Fasting Plasma Glucose)		Change from Visit 1(Baseline Visit) in FPG at Visit 5(week 16)	No
Secondary	Weight		Change from Visit 1(Baseline Visit) in weight at Visit 5(week 16)	No
Secondary	BMI		Change from Visit 1(Baseline Visit) in BMI at Visit 5(week 16)	No
Secondary	HbA1c <7.0%		The proportion of patients who achieve an HbA1c<7.0% at Visit 5(week 16)	No
Secondary	HbA1c <6.5%		The proportion of patients who achieve an HbA1c<6.5% at Visit 5(week 16)	No
Secondary	Total Cholesterol		Change from Visit 1(Baseline Visit) in Total Cholesterol at Visit 5(week 16)	No
Secondary	LDL Cholesterol		Change from Visit 1(Baseline Visit) in LDL Cholesterol at Visit 5(week 16)	No
Secondary	HDL Cholesterol		Change from Visit 1(Baseline Visit) in HDL Cholesterol at Visit 5(week 16)	No
Secondary	Triglyceride		Change from Visit 1(Baseline Visit) in Triglyceride at Visit 5(week 16)	No
Secondary	C-peptide		Change from Visit 1(Baseline Visit) in C-peptide at Visit 5(week 16)	No
Secondary	Insulin		Change from Visit 1(Baseline Visit) in insulin at Visit 5(week 16)	No
Secondary	hsCRP		Change from Visit 1(Baseline Visit) in hsCRP at Visit 5(week 16)	No
Secondary	HOMA-ß		Change from Visit 1(Baseline Visit) in HOMA-ß at Visit 5(week 16)	No
Secondary	HOMA-IR		Change from Visit 1(Baseline Visit) in HOMA-IR at Visit 5(week 16)	No